A185490 Stock Overview
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
EyeGene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,135.00 |
| 52 Week High | ₩4,895.00 |
| 52 Week Low | ₩2,800.00 |
| Beta | 1.73 |
| 1 Month Change | -5.00% |
| 3 Month Change | 4.33% |
| 1 Year Change | -29.15% |
| 3 Year Change | -83.57% |
| 5 Year Change | -72.94% |
| Change since IPO | -71.28% |
Recent News & Updates
Shareholder Returns
| A185490 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -0.8% | 5.4% | 3.4% |
| 1Y | -29.2% | 6.7% | 7.1% |
Return vs Industry: A185490 underperformed the KR Biotechs industry which returned 6.6% over the past year.
Return vs Market: A185490 underperformed the KR Market which returned 4.7% over the past year.
Price Volatility
| A185490 volatility | |
|---|---|
| A185490 Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A185490 has not had significant price volatility in the past 3 months.
Volatility Over Time: A185490's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 82 | Won-Il Yoo | www.eyegene.co.kr |
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. The company’s products in pipeline include EG-Mirotin, which has completed Phase IIa clinical trial for the treatment of diabetic retinopathy; EG-Decorin that completed Phase II clinical trial to treat pressure ulcers and wound healing; EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury; EG-TB, a preclinical product for tuberculosis vaccine; and EG-HPV that has completed Phase I clinical trial for the treatment of cervical cancer. It also offers EG-Vac for the treatment of immune adjuvant; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-HZ, which has completes phase I trials for the treatment of herpes zoster.
EyeGene Inc. Fundamentals Summary
| A185490 fundamental statistics | |
|---|---|
| Market cap | ₩84.74b |
| Earnings (TTM) | -₩21.11b |
| Revenue (TTM) | ₩3.13b |
27.1x
P/S Ratio-4.0x
P/E RatioIs A185490 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A185490 income statement (TTM) | |
|---|---|
| Revenue | ₩3.13b |
| Cost of Revenue | ₩1.26b |
| Gross Profit | ₩1.87b |
| Other Expenses | ₩22.97b |
| Earnings | -₩21.11b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -780.84 |
| Gross Margin | 59.68% |
| Net Profit Margin | -675.30% |
| Debt/Equity Ratio | 4.0% |
How did A185490 perform over the long term?
See historical performance and comparison